Article Highlights
The Dexcom G7 represents the latest advancement in continuous glucose monitoring technology, building on years of clinical experience while introducing meaningful improvements that address real-world user needs. As Dexcom's newest CGM system available in Canada, the G7 combines enhanced convenience with proven accuracy, offering a streamlined experience for people living with diabetes. This article explores how the G7 works, what sets it apart from previous systems, and whether it might be the right choice for your diabetes management.
The most immediately noticeable change with the G7 is its physical design. Unlike previous systems that used separate sensor and transmitter components, the G7 integrates everything into a single, discreet wearable unit. This all-in-one sensor is roughly 60% smaller than the G6 sensor and transmitter combined, making it less noticeable under clothing and more comfortable during sleep or physical activity.
The streamlined design eliminates the need to snap a transmitter onto each new sensor. You simply apply the complete unit every 10 days, significantly simplifying the sensor change process. The smaller profile also means less bulk at the insertion site, which many users find particularly valuable during sports, swimming, or other activities where a lower profile matters.
The improvements in the G7 go beyond physical size. Dexcom focused on addressing specific user feedback and clinical needs that emerged from years of real-world G6 use.
Dramatically faster warmup: The 30-minute warmup time is a substantial improvement over the G6's two-hour wait. This means you can apply a new sensor in the morning and have reliable readings by the time you sit down for breakfast, or change your sensor before bed and wake up with full monitoring in place.
Simplified sensor changes: With no separate transmitter to manage, track, or replace every three months, the G7 reduces the overall complexity of CGM use. You apply a complete new sensor unit every 10 days, and that's it.
Grace period option: When your 10-day sensor session ends, the G7 offers an optional 12-hour grace period. If you choose to use it, you can continue wearing your sensor for up to 12 additional hours while it continues to provide readings.
Maintained accuracy with faster response: Clinical studies show the G7 maintains the high accuracy standards established by the G6, with a mean absolute relative difference (MARD) of approximately 8.2% in adults and 8.1% in pediatric users.
If you're currently using the G6 or considering which Dexcom system to choose, this comparison will help you understand the practical differences between these two systems.
For many users, the G7 represents a meaningful improvement in convenience without compromising the accuracy and reliability established by the G6. Both G6 and G7 now support major AID systems in Canada, so the choice often depends on personal preference, coverage, and device features.
Choose the G7 if:
- You want the smallest, most discreet sensor design
- You value the 30-minute warmup for greater flexibility
- You prefer simplicity without transmitter management
- You use CGM as a standalone system or with multiple daily injections
- You are planning AID with a pump that now supports G7
Choose the G6 if:
- You are on an older AID setup or pump firmware that hasn't yet been updated for G7
- Your insurance or coverage specifically requires G6
- You've had excellent results with G6 and prefer to continue what's working
- Your diabetes clinic specifically supports and trains on G6
Every 10 days, you apply a fresh G7 sensor using the integrated one-button applicator. The insertion process is quick and designed to be as comfortable as possible. Approved wear sites include:
- Ages 7 and older: Back of the upper arm (and, in some Canadian materials, abdomen)
- Ages 2–6: Back of the upper arm or upper buttocks
The 30-minute warmup begins immediately after application. When the session ends, you have the option to use the 12-hour grace period to extend monitoring until you're ready to apply a new sensor.
To ensure your sensor stays securely attached for the full wear period, preparation matters. Clean the insertion site thoroughly with soap and water, avoiding any lotions, oils, or moisturizers that might interfere with adhesion. Let the area dry completely before application. Many users find that applying the sensor in the evening allows adhesive to set overnight. If you engage in vigorous exercise, swimming, or activities that cause heavy sweating, consider using an overlay patch for additional security.
The G7 measures glucose in the interstitial fluid rather than directly in your blood. This creates a physiological lag of approximately 5–10 minutes between changes in blood glucose and what the CGM displays. During stable glucose periods, this lag is minimal. During rapid rises or falls, you may notice the CGM reading differs from a fingerstick test taken at the same moment.
Trend arrows indicate rate of change:
- Flat arrow (→): Glucose changing slowly (less than 1 mg/dL per minute)
- Single arrow up (↑) or down (↓): Moderate rate of change (1–2 mg/dL per minute)
- Double arrows up (↑↑) or down (↓↓): Rapid change (more than 2 mg/dL per minute)
You can customize high and low glucose alerts to match your management goals. The Urgent Low Soon alert warns you when the system predicts you'll reach 55 mg/dL within approximately 20 minutes, giving you time to treat and prevent severe hypoglycemia.
Dexcom Clarity helps you identify meaningful patterns over days and weeks. The Ambulatory Glucose Profile (AGP) overlays multiple days onto a single 24-hour timeline, revealing consistent patterns that might not be obvious when looking at individual days. Clarity reports show time in range, time above and below range, glucose variability, and a Glucose Management Indicator (GMI).
The Dexcom Follow app lets you share your real-time glucose data with up to 10 followers who can receive alerts and monitor your readings. This provides peace of mind for parents monitoring children with diabetes, partners providing overnight support, and caregivers.
The G7's clinical validation demonstrates high accuracy with a MARD of approximately 8.2% in adults and 8.1% in pediatric participants. Accuracy remained consistent across all glucose ranges and throughout the full 10-day wear period.
The G7 is indicated for people with diabetes ages 2 and older, including those with type 1, type 2, and gestational diabetes. It is most commonly prescribed for those on intensive insulin therapy. High doses of acetaminophen (more than 1,000 mg every 6 hours in adults) can make Dexcom readings falsely higher than your actual blood sugar. If you routinely need high-dose acetaminophen, work closely with your diabetes team and use fingerstick testing for critical decisions.
In Canada, out-of-pocket pharmacy prices for Dexcom G7 sensors typically range around $84–$104 CAD per 10-day sensor (about $250–$310 per month for three sensors). Dexcom Canada also offers a patient benefit/copay program that can provide up to 20% off the pharmacy sensor price. Many private insurance plans cover CGM for people on intensive insulin therapy. Before ordering, verify your specific insurance coverage, provincial program eligibility, and out-of-pocket costs.
Getting started with the Dexcom G7 generally involves a few steps. A prescription is required when using insurance or provincial coverage programs, but it is not required for out-of-pocket purchases.
- Prescription and consultation (for insurance-covered use): Discuss with your diabetes care team whether CGM is appropriate for your treatment regimen and goals.
- Out-of-pocket purchases (no prescription required): The Dexcom G7 can be obtained without a prescription.
- Verify coverage: Check provincial program eligibility and private insurance coverage, including any prior authorization requirements.
- Training and onboarding: Dexcom provides video tutorials, printed guides, and phone support.
Endor Health makes it simple to access the Dexcom G7 with fast delivery and comprehensive support. We guide you through the entire process, from verifying coverage to getting your first sensor up and running. Download the Endor Health app to get started with the G7.
- Dexcom, Inc. Dexcom G7 CGM System User Guide. Retrieved from https://www.dexcom.com/
- Martens, T., Beck, R.W., Bailey, R., et al. (2021). Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin. JAMA, 325(22), 2262–2272.
- Laffel, L.M., Kanapka, L.G., Beck, R.W., et al. (2020). Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes. JAMA, 323(23), 2388–2396.
- Beck, R.W., Riddlesworth, T., Ruedy, K., et al. (2017). Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA, 317(4), 371–378.
The information in this article is for educational purposes only and should not replace advice from your healthcare provider. Always consult with your diabetes care team before making changes to your diabetes management.
For more information:
- Dexcom Canada: 1-888-738-3646
- Website: www.dexcom.com/en-ca
